<DOC>
	<DOCNO>NCT00755638</DOCNO>
	<brief_summary>Single center , randomize , single dose study evaluate safety , tolerability , pharmacokinetic pharmacodynamic effect ACE-031 healthy postmenopausal volunteer</brief_summary>
	<brief_title>A Safety , Tolerability , Pharmacokinetic Pharmacodynamic Study ACE-031 ( ActRIIB-IgG1 ) Healthy Postmenopausal Volunteers</brief_title>
	<detailed_description />
	<criteria>Key 1 . Subject postmenopausal woman , 4575 year old ( inclusive ) 2 . Subject body mass index ( BMI ) &gt; 18.5 &lt; 30 3 . Subject must give write informed consent Key 1 . Subject history malignancy . However , subject history excise treat basal cell carcinoma , cervical carcinoma insitu , less equal 2 squamous cell carcinoma eligible participate study . 2 . Subject history clinically significant ( determined Investigator ) cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease . 3 . Subjects chronic stable disease include migraine , hypertension , hyperthyroid disorder , hypothyroid disorder , gastroesophageal reflux disease , mild depression/anxiety exclude unless investigator safety compliance concern study entry . 4 . Subject history opportunistic infection ( e.g . invasive candidiasis pneumocystis pneumonia ) . 5 . Subject serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , septicemia ) within 3 month prior screen . 6 . Subject history severe allergic anaphylactic reaction . 7 . Subject surgery within previous 3 month ( minor cosmetic surgery minor dental procedure ) . 8 . Subject fever ( body temperature &gt; 38°C ) symptomatic viral bacterial infection within 2 week prior dose . 9 . Subject positive Tuberculin skin test ( Mantoux ) 10 . Subject history hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) , human immunodeficiency virus ( HIV ) . 11 . Subject recent clinically significant history drug alcohol abuse , test positive urine screen alcohol drug abuse . 12 . Subject consume alcohol within 48 hour prior dose . 13 . Subject donate lose ≥ 499 mL whole blood within 56 day prior study drug administration . 14 . Subject take hormone replacement therapy within 3 month prior study enrollment , plan begin hormone replacement therapy time study .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>